Oil Consumption and Cholesterol

May 8, 2023 updated by: Jamie Cooper, PhD, University of Georgia

Comparison of Blood Lipids From Diets Enriched With Cottonseed Oil Versus Olive Oil in Adults With High Cholesterol

More than 31 million U.S. adults have high total cholesterol and over 73 million U.S. adults have high LDL cholesterol. Cottonseed oil (CSO) is found readily in our food supply, and recent research has shown improvements in blood lipids following CSO consumption in healthy adults with normal cholesterol profiles. To date, however, there are no published studies on the effects of CSO-enriched diets on blood lipids and markers of health in an older population with hypercholesterolemia. Therefore, the purpose of this study is to test the health effects of a diet rich in CSO against a diet rich in olive oil to determine if the CSO-enriched diet will show greater improvements in blood lipids and other health markers in adults with high cholesterol levels. If CSO in the diet is found to improve these markers, these study findings could lead to improvements in health.

Study Overview

Detailed Description

This was a single-blind, randomized controlled trial. Investigators recruited subjects with hypercholesterolemia (high blood cholesterol levels). Subjects were randomized into one of two groups: (1) Cottonseed oil (CSO), (2) Olive oil (OO). The interventions consist of identical foods that are only different in the respective oil they are prepared with.

There was a screening visit and 3 testing visits: Baseline (visit 2), mid-visit at week 4 (visit 6), and post-visit at week 8 (visit 10). Anthropometrics, questionnaires, and a fasting blood sample were collected at each visit. At visits 2 and 10 participants participated in a saturated fatty acid meal challenge in which additional blood and metabolism measurements were collected. Visits 3-9 represent weekly meal pickups, with the exception of visit 6 which is also a testing visit.

Hypothesis: Investigators hypothesized that enrichment of the diet with CSO would result in significantly greater improvements in blood lipids, metabolism, and appetite compared to the OO group.

Study Type

Interventional

Enrollment (Actual)

112

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Georgia
      • Athens, Georgia, United States, 30605
        • University of Georgia

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

28 years to 73 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • 30-75 year old
  • body mass index (BMI) between 18.5-39.9 kg/m2
  • higher cholesterol levels indicated by "At Risk/Borderline High" in two or more of the variables (total cholesterol: 180-239 mg/dL, LDL cholesterol 110-159 mg/dL, triglycerides 130-199 mg/dL) or "High" in either total cholesterol (240 mg/dL and higher) or LDL (160 mg/dL or higher), and having triglyceride levels less than 350mg/dL.

Exclusion Criteria:

  • participants with familial hypercholesterolemia
  • LDL levels greater than the 95th percentile based on age and sex
  • HDL levels lower than the 20th percentile based on age and sex
  • women on hormone replacement therapy for less than 2 years
  • individuals who regularly exercise more than 3 h/w
  • weight gain or loss more than 5% of their body weight in the past 3 months
  • plans to begin a weight loss/exercise regiment during the trial
  • history of medical or surgical events that could affect digestion or swallowing
  • gastrointestinal surgeries
  • conditions or disorders
  • any chronic or metabolic diseases
  • atherosclerosis
  • previous MI or stroke
  • cancer
  • fasting blood glucose levels greater than 126 mg/dL
  • blood pressure greater than 180/120 mmHg
  • medication use affecting digestion and absorption
  • medication use affecting metabolism (e.g. thyroid meds)
  • lipid-lowering medications
  • medications for diabetes
  • steroid/hormone therapies
  • a medically prescribed or special diet
  • food allergies (specific for the foods made in the study)
  • taking fish oil and calciumfloroboron supplements
  • excessive alcohol use (greater than 3 drinks/d for men; greater than 2 drinks/d for women)
  • tobacco or nicotine use

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Cottonseed Oil
Participants are given foods enriched with cottonseed oil and instructed on how to substitute study foods into their diet to maintain caloric balance
Participants are provided about 60% of their required energy for 8 weeks as foods from a 5 day cycle menu that are enriched with Cottonseed Oil
Active Comparator: Olive Oil
Participants are given foods enriched with olive oil and instructed on how to substitute study foods into their diet to maintain caloric balance
Participants are provided about 60% of their required energy for 8 weeks as foods from a 5 day cycle menu that are enriched with Olive Oil

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in baseline fasting blood lipids at weeks 4 and 8
Time Frame: Baseline, 4 weeks, 8 weeks
Total Cholesterol (mg/dL), high-density lipoprotein (HDL) cholesterol (mg/dL), triglycerides (mg/dL), low-density lipoprotein (LDL) cholesterol (mg/dL), apolipoprotein B (mg/dL)
Baseline, 4 weeks, 8 weeks
Change in baseline lipoprotein (a), lipoprotien particle number and size at weeks 4 and 8
Time Frame: Baseline, 4 weeks, 8 weeks
Low density lipoprotien (LDL) particle number (nmol/L), LDL small (nmol/L), HDL large (nmol/L), LDL medium (nmol/L), lipoprotein (a) (nmol/L).
Baseline, 4 weeks, 8 weeks
Change in baseline low density lipoprotien (LDL) peak size at weeks 4 and 8
Time Frame: Baseline, 4 weeks, 8 weeks
LDL peak size (angstrom)
Baseline, 4 weeks, 8 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Baseline Blood Concentration of Hunger and Satiety Hormones over 8 weeks
Time Frame: measured at weeks 1 and 8 at fasting and for 5 hours postprandially
Blood samples will be collected to measure Peptide tyrosine tyrosine (YY) (pg/mL), Cholecystokinin (CCK) (pg/mL), Ghrelin (pg/mL), Glucagon-like peptide 1 (GLP1) (pg/mL)
measured at weeks 1 and 8 at fasting and for 5 hours postprandially
Change in Height over 8 weeks
Time Frame: measured at weeks 1, 4, and 8 at fasting
Height measured in centimetres
measured at weeks 1, 4, and 8 at fasting
Change in weight over 8 weeks
Time Frame: measured at weeks 1, 4, and 8 at fasting
weight measured in pounds and kilograms
measured at weeks 1, 4, and 8 at fasting
change in blood pressure over 8 weeks
Time Frame: measured at weeks 1, 4, and 8 at fasting
both systolic and diastolic blood pressure measured in millimetres of mercury (mmHg)
measured at weeks 1, 4, and 8 at fasting
change in waist circumference over 8 weeks
Time Frame: measured at weeks 1, 4, and 8 at fasting
waist circumference measured in centimetres
measured at weeks 1, 4, and 8 at fasting
change in hip circumference over 8 weeks
Time Frame: measured at weeks 1, 4, and 8 at fasting
hip circumference measured in centimetres
measured at weeks 1, 4, and 8 at fasting
change in total body fat percentage over 8 weeks
Time Frame: measured at weeks 1, 4, and 8 at fasting
total body fat percentage measured as percent of total body mass
measured at weeks 1, 4, and 8 at fasting
change in Blood glucose concentration responses (glycemia) over 8 weeks
Time Frame: measured at week 1 and 8 at fasting and for 5 hours postprandially
blood samples are collected to measure blood glucose concentration (mg/dL) in response to saturated fatty acid meal
measured at week 1 and 8 at fasting and for 5 hours postprandially
change in Blood insulin concentration responses (glycemia) over 8 weeks
Time Frame: measured at week 1 and 8 at fasting and for 5 hours postprandially
blood samples are collected to measure blood insulin concentration (uU/mL) in response to saturated fatty acid meal
measured at week 1 and 8 at fasting and for 5 hours postprandially
change in blood triglyceride meal responses over 8 weeks
Time Frame: measured at week 1 and 8 at fasting and for 5 hours postprandially
Triglyceride (mg/dL) response to saturated fatty acid meal
measured at week 1 and 8 at fasting and for 5 hours postprandially
change in non-esterified free fatty acid (NEFA) meal responses over 8 weeks
Time Frame: measured at week 1 and 8 at fasting and for 5 hours postprandially
NEFA (mEq/dL) response to saturated fatty acid meal
measured at week 1 and 8 at fasting and for 5 hours postprandially
change in Fat oxidation over 8 weeks
Time Frame: measured at week 1 and 8 at fasting and for 3.5 hours postprandially
measured (g/hr) via indirect calorimetry
measured at week 1 and 8 at fasting and for 3.5 hours postprandially
change in Carbohydrate oxidation over 8 weeks
Time Frame: measured at week 1 and 8 at fasting and for 3.5 hours postprandially
measured (g/hr) via indirect calorimetry
measured at week 1 and 8 at fasting and for 3.5 hours postprandially
change in Resting metabolic rate (RMR) over 8 weeks
Time Frame: measured at week 1 and 8 at fasting and for 3.5 hours postprandially
RMR (kcals/d) measured via indirect calorimetry
measured at week 1 and 8 at fasting and for 3.5 hours postprandially
change in Respiratory exchange ratio (RER) over 8 weeks
Time Frame: measured at week 1 and 8 at fasting and for 3.5 hours postprandially
measured (VCO2/Vo2) via indirect calorimetry
measured at week 1 and 8 at fasting and for 3.5 hours postprandially
change in subjective appetite over 8 weeks
Time Frame: measured at week 1 and 8 at fasting and for 5 hours postprandially in 30 minuet intervals; also measured once per hour after the subject leaves the lab until they go to bed
hunger, fullness, prospective consumption, and desire to eat measured via a Visual Analog Scale (VAS). VAS uses an unmarked 10 centimetre line and asks the subject to answer the connected question by placing a tick mark on the line as though it is a spectrum from 0 to 100 percent with the right being in the most agreement (i.e. extremely hungry in response to how hungry are you) and the left being the most disagreement (i.e. extremely not hungry in response to how hungry are you). Answers will be measured in centimetres in response to questions about hunger, fullness, prospective consumption, and desire to eat.
measured at week 1 and 8 at fasting and for 5 hours postprandially in 30 minuet intervals; also measured once per hour after the subject leaves the lab until they go to bed

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Perceived Stress over 8 weeks
Time Frame: measured at week 1, 4, and 8 at fasting
perceived Stress Scale is a questionnaire asking 10 questions about the subject's feelings of stress in the past month. There are 5 possible answers, never, almost never, sometimes, fairly often, very often with corresponding scores of 0 - 4 respectively. Scores for all questions will be added up as in indication of stress level. Higher perceived stress scale scores correspond to higher stress levels.
measured at week 1, 4, and 8 at fasting

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 14, 2018

Primary Completion (Actual)

June 8, 2021

Study Completion (Actual)

June 8, 2021

Study Registration Dates

First Submitted

April 30, 2020

First Submitted That Met QC Criteria

May 16, 2020

First Posted (Actual)

May 21, 2020

Study Record Updates

Last Update Posted (Actual)

May 10, 2023

Last Update Submitted That Met QC Criteria

May 8, 2023

Last Verified

May 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • STUDY00005869

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

The plan is to share group averages through publication

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypercholesterolemia

Clinical Trials on Cottonseed Oil

3
Subscribe